Long-term outcomes with use of the CrossBoss and stingray coronary CTO crossing and re-entry devices.
The Boston Scientific CrossBoss and Stingray Coronary CTO Crossing and Re-Entry devices (formerly the BridgePoint Medical System) can improve success rates in chronic total occlusion (CTO) percutaneous coronary intervention (PCI), but there are no published data on long-term clinical outcomes. The acute and long-term outcomes of 170 consecutive patients who underwent CTO PCI at our institution were reviewed, including 60 patients in whom the CrossBoss and Stingray devices were used and 110 patients treated with other crossing strategies. Baseline characteristics were similar between the two cohorts. Patients in whom the CrossBoss/Stingray was utilized had more prior CTO PCI attempts (13.1% vs 1.6%; P=.003), required longer fluoroscopy times (46 ± 22 minutes vs 35 ± 20 minutes; P<.001), higher contrast dose (390 ± 141 mL vs 323 ± 132 mL; P>.99), and more guidewires for lesion crossing (8.0 ± 6.5 vs 4.7 ± 2.3; P<.001), but procedural success (75.8% vs 76.2%; P>.99) and major complication rates (4.8% vs 3.2%; P=.69) were similar. During a median follow-up of 1.81 years, the CrossBoss/Stingray group had no difference in target lesion revascularization (40.9% vs 29.6%; P=.13) and major adverse clinical events (40.3% vs 35.2%; P=.42). Use of the CrossBoss/Stingray devices for CTO PCI is associated with equally high success and equally low complication rates as other techniques, both immediately post procedure and during long-term follow-up, in spite of its use in higher complexity cases.